Key terms
About MESO
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest MESO news
Apr 23
8:46am ET
Largest borrow rate increases among liquid names
Apr 17
6:58am ET
Mesoblast Director Boosts Share Ownership
Apr 17
6:58am ET
Mesoblast Applies for Quotation of New Shares
Apr 17
6:58am ET
Mesoblast Issues New Employee Incentive Options
Apr 17
6:57am ET
Mesoblast Reports Cessation of 80,000 Options
Apr 15
8:46am ET
Largest borrow rate increases among liquid names
Apr 12
8:46am ET
Largest borrow rate increases among liquid names
Mar 28
10:59am ET
Biotech Alert: Searches spiking for these stocks today
Mar 21
6:57am ET
Mesoblast Limited Announces New Share Issue
Mar 14
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Mar 13
11:07am ET
Biotech Alert: Searches spiking for these stocks today
Mar 12
6:36am ET
Mesoblast (MESO) Gets a Hold from Piper Sandler
Mar 03
7:16am ET
Mesoblast Limited (MEOBF) Receives a Buy from Jefferies
Feb 29
7:48am ET
Mesoblast (MESO) Gets a Hold from Piper Sandler
Feb 14
7:50pm ET
FDA grants Mesoblast orphan-drug designation for Revascor
Feb 14
2:56pm ET
Mesoblast treatment of Hypoplastic Left Heart Syndrome gets orphan status
No recent press releases are available for MESO
MESO Financials
Key terms
Ad Feedback
MESO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
MESO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range